The anti-inflammatory effects of activated protein C (APC) have lead to its recent approval for the treatment of sepsis. Although the endothelial cell protein C receptor (EPCR) plays a crucial role in APC's protective roles in septicemia, the precise signaling mechanism of the protease APC remains unclear. In fibroblast overexpression systems, we find that APC activates protease activated receptors (PAR) 1 and 2 in an EPCR-dependent manner. Human endothelial cells (HUVECs) express PAR1, PAR2 and EPCR. Stimulation of HUVECs with either APC, or specific receptor activating peptides for PAR1 or PAR2, show that all three agonists induce a very similar set of early response genes as assessed by high density microarray analysis. Only the transcript for monocyte chemo-attractant protein-1 (MCP-1) was selectively induced by APC and the PAR1 agonist, but not by the PAR2 agonist. APC-mediated MAP kinase phosphorylation and gene induction were inhibited by cleavage blocking antibodies to PAR1, demonstrating that APC signals exclusively through PAR1 in endothelial cells. MCP-1 is protective in animal models of endotoxemia, suggesting that APC may prevent lethality in sepsis by inducing MCP-1 expression through EPCRdependent activation of endothelial cell PAR1. These data demonstrate unexpected protective functions of the major thrombin receptor PAR1 in endothelial cells.
INTRODUCTION
Tissue factor (TF) initiated coagulation in sepsis triggers a lethal response 1-3 that may involve coagulation protease mediated pro-inflammatory signaling through Gprotein coupled PARs. [4] [5] [6] [7] The protein C (PC) pathway protects animals from Escherichia coli induced lethality 8, 9 and APC reduces mortality in patients with severe sepsis. 10 PC bound to EPCR is activated by a coagulation feedback loop in which traces of thrombin, once bound to thrombomodulin, specifically activate PC (Fig. 1) . 11 APC is a trypsin-like coagulation protease and PARs serve as the cellular sensors for these enzymes. 4, 5 The PC anticoagulant pathway operates on endothelial cells that express PAR1 and PAR2 along with EPCR. Proteolytic signaling by APC induces protective responses in endothelial cells, 12 but the involvement of PARs in this process is unclear.
MATERIALS AND METHODS

Reporter gene assay
The murine PAR-deficient M6-11 cell line was co-transfected with an egr-1 promoter luciferase reporter construct and the indicated cDNAs. A mutant EPCR construct that lacks PC/APC binding activity was generated by replacing Tyr154 with Ala using oligonucleotide-directed mutagenesis. 13 Overnight serum-starved cells were incubated with agonists for 5 h. Thrombin, APC, hirudin, the PAR1 agonist peptide TFLLRNPNDK, the PAR2 agonist peptide SLIGRL, and monoclonal anti-PAR1 antibodies ATAP2 (used at 10 mg/ml) and WEDE15 (used at 20 mg/ml) were as described previously. 7, 14, 15 
MAP kinase phosphorylation in endothelial cells
HUVECs were incubated for 5 h with fresh M199 containing 2% serum prior to agonist stimulation as above. Erk1/2 phosphorylation was analyzed by Western blotting after 6 min of stimulation. Active site modified APC (APC-CK) was generated by incubation of APC with 0.5 mM H-D-Phe-L-Phe-Arg chloromethylketone (Bachem Bioscience Inc., King of Prussia, PA, USA) followed by extensive dialysis. APC-CK had less than 1% remaining amidolytic activity and to block APC binding to EPCR, 100 nM APC-CK was added prior to agonist stimulation. To block PAR1 cleavage, anti-PAR1 antibodies were added 10 min prior to agonist stimulation.
Microarray analysis
Confluent human umbilical vein endothelial cells HUV-EC-C (ATCC CRL 1730) were serum deprived for 5 h, followed by stimulation with 10 mM TFLLRNPNDK, 100 mM SLIGRL, or 10 nM APC/100 nM hirudin, for 90 min at 37°C. Total RNA was isolated and analyzed by hybridization to the HG-U95Av2 array (Affymetrix, Santa Clara, CA, USA). Three independent experiments analyzing gene induction by PAR1, PAR2, or APC yielded 12 data sets from high-density microarrays with 9 comparisons between the agonists and control. An average fold-induction for the three independent experiments was obtained by calculating the means of the logarithm of the individual fold-increases for each agonist. To eliminate non-expressed and highly variable genes, the following criteria were set for genes shown: (i) the gene's expression level had to be scored 'present' by the GeneChip software algorithm in more than two of the 12 data sets; (ii) GeneChip 3.1 comparison analysis of stimulated versus control had to score 'increased' in more than one out of the 9 comparisons; and (iii) the ratio of the average-fold induction for all agonists and the mean of the standard deviations for the inductions by each agonist had to be larger than 1.
TaqMan real-time PCR
For TaqMan (Applied Biosystems, Foster City, CA, USA) real-time RT-PCR 4 mg total cellular RNA from stimulated primary HUVECs was reverse transcribed followed by RNAse treatment using the Superscript Kit (Invitrogen, Carlsbad, CA, USA). TaqMan probes were custom designed for genes of interests.
Statistics
Significance of differences was evaluated by paired t-test. 
RESULTS
PAR1-deficient murine fibroblasts are not activated by proteases, unless transfected with an appropriate PAR. 6, 7 We exploited the unresponsiveness of these cells to APC to characterize the requirement for protease signaling by APC. Stimulation with APC was performed in the presence of 100 nM hirudin, which blocks all cell surface thrombin-mediated PAR1 signaling. 15 PAR1-deficient fibroblasts were responsive to 20 nM APC only when EPCR was co-expressed with a PAR ( Fig. 2A ). Expression of EPCR or PAR2 alone or co-expression of PAR2 with an EPCR mutant deficient in APC binding 13 failed to support APC signaling ( Fig. 2A) . Thus, only EPCR-bound APC can efficiently activate PARs. Co-expression of EPCR and PAR1 also resulted in responsiveness to APC ( Fig. 2A) . Like thrombin signaling, APC signaling was inhibited by PAR1 cleavage-blocking antibodies, whereas anti-PAR1 antibodies did not prevent signaling by the direct PAR1 agonist or an unrelated G-protein coupled receptor agonist, excluding non-specific PAR1 desensitization. Thus, APC signals through a proteolytic mechanism and not through a protease-independent receptor cross-talk between EPCR and PARs.
Although the heterologous over-expression experiments demonstrated that EPCR-bound APC could activate PAR1 and PAR2, PAR cleavage specificity of EPCR-bound APC in primary endothelial cells remained to be established. In endothelial cells, APC-induced MAP kinase phosphorylation, a common response of PAR1 and PAR2 signaling (Fig. 2B ). Active site blocked APC failed to induce MAP kinase phosphorylation, consistent with a proteolytic mechanism. Moreover, APC, but not thrombin, responses were inhibited by a 10-fold molar excess of active site-blocked APC that competes for EPCR binding, confirming receptor dependence of APC signaling in endothelial cells. Cleavage blocking anti-PAR1 antibodies inhibited APC signaling, without affecting the response to the PAR2 agonist peptide. Thus, MAP kinase phosphorylation by the PC pathway on endothelial cells was dependent on PAR1.
To determine whether PAR activation accounts for APC-dependent gene induction in endothelial cells, large scale mRNA expression profiles were determined for endothelial cells stimulated with APC or with selective agonist peptides for PAR1 or PAR2. Stimulation for 90 min was chosen to capture both early transcription-related and delayed effector gene induction events. In three independent experiments, 1% of the ~7000 represented genes were reproducibly up-regulated by stimulation with APC or a PAR agonist. PAR1 and PAR2 agonists induced most genes to a similar extent (Fig. 3A) with the prominent exception of the transcript of monocyte chemo-attractant protein-1 (MCP-1), which was only induced by the PAR1 agonist. Overall, gene induction by APC correlated with direct agonist stimulation of PAR1 (Fig. 3B ) as well as PAR2 (Fig. 3C) . Some genes were induced by PAR agonist peptides, but not by APC stimulation. Most significantly, all the APC-induced transcripts were also induced by PAR1 (Fig. 3B) . Thus, all transcriptional responses to APC signaling of endothelial cells are accounted for by PAR1 signaling. The concordant upregulation of protective genes by PAR1 agonist and APC 16 suggests that all anti-inflammatory and anti-apoptotic Activated protein C signals through the thrombin receptor PAR1 in endothelial cells 319 effects of APC signaling are PAR-mediated in endothelial cells. In time-course experiments in primary endothelial cells, MCP-1 was similarly induced by APC and the PAR1 agonist, but not by direct activation of PAR2, whereas all three agonists induced the nuclear hormone receptor TR3 with similar kinetics (Fig. 4A ). As expected, anti-PAR1 antibodies blocked the induction of the PAR1-specific MCP-1 gene by APC, but anti-PAR1 antibodies also inhibited the APC-dependent induction of genes responsive to direct agonist stimulation of either PAR1 or PAR2 stimulation (Fig. 4B) , demonstrating that PAR2 cannot substitute for PAR1 in APC signaling of endothelial cells. 
DISCUSSION
How can activation of the prototypical thrombin receptor PAR1 by APC be relevant if the generation of APC is thrombin dependent? Infusion of low concentrations of thrombin into primates does not elicit platelet activation, a highly sensitive PAR-dependent response. Rather, thrombin activates the PC pathway 17 due to thrombin's recruitment to endothelial cell thrombomodulin and thrombomodulinbound thrombin does not efficiently induce PAR signaling. 18 Given that thrombin/thrombomodulin activates EPCRbound PC 19 and that EPCR-bound APC activates PAR1, the physiological activation of the PC pathway emerges as a highly relevant activator of protective PAR1 signaling on endothelial cells. EPCR's protective roles in endotoxin-challenged animals 8 emphasize the importance of this receptor cascade for sepsis. The inflammatory cytokine production in sepsis disables the physiological anticoagulant pathway by down-regulating thrombomodulin, but EPCR remains detectable on thrombomodulin-depleted endothelial cells. 20 Therapeutically administered APC may utilize residual EPCR as a co-receptor in signaling to achieve protection from severe sepsis. 10 In the escalation of the sepsis syndrome, thrombin is unlikely to reproduce the endothelium-restricted protective PAR1 signaling of APC, because thrombin's targets include PARs on a number of cell types that are activated in the context of microthrombotic organ dysfunction. Unexpectedly, MCP-1 was identified as a gene that is selectively up-regulated by APC-dependent PAR1 signaling in endothelial cells. In systemically and locally induced sepsis models, MCP-1 is protective. 21, 22 In addition to the direct endothelial protective functions of APC, local MCP-1 induction by APC may promote indirect anti-inflammatory effects through an immuno-modulatory chemokine network that controls the host defense in sepsis.
